Microarray-based analysis of renal complement components reveals a therapeutic target for lupus nephritis

Area of Science:

• Nephrology
• Immunology
• Molecular Biology

Background:

• Lupus nephritis (LN) involves abnormal kidney pathways and complement system activation.
• Identifying complement-related therapeutic targets is crucial for LN treatment.

Purpose of the Study:

• To screen abnormal pathways and complement components in LN kidneys.
• To investigate the role of complement activation and TGFβ1 in LN pathogenesis.

Main Methods:

• KEGG and GO enrichment assays on kidney microarray data from LN patients and NZB/W mice.
• Immunohistochemistry, immunofluorescence, RT-qPCR, and ELISA to measure renal expression of complement proteins and cytokines.
• Primary cell culture and TGFβ1 antagonist treatment to study TGFβ1-C3 interactions.

Main Results:

• Complement activation pathway identified as a key pathogenic pathway in LN.
• Increased renal expression of complement factors (C1qa, C1qb, C3, C3aR1, C5aR1) at mRNA and protein levels.
• Significant correlation between TGFβ1 and C3 expression; TGFβ1 promotes C3 synthesis, and its inhibition reduces C3 levels and complement deposition.

Conclusions:

• Elevated C3 and complement factors are present in LN kidneys at disease onset.
• C3 may contribute to albuminuria and LN pathogenesis.
• TGFβ1 inhibition offers a potential therapeutic strategy for LN by blocking C3 synthesis and complement component deposition.